Cross-clade detection of HIV-1-specific cytotoxic T lymphocytes does not reflect cross-clade antiviral activity
- PMID: 18184090
- DOI: 10.1086/525281
Cross-clade detection of HIV-1-specific cytotoxic T lymphocytes does not reflect cross-clade antiviral activity
Abstract
The genetic divergence of human immunodeficiency virus (HIV)-1 into distinct clades is a serious consideration for cytotoxic T lymphocyte (CTL)-based vaccine development. Demonstrations that CTLs can cross-recognize epitope sequences from different clades has been proposed as offering hope for a single vaccine. Cross-clade CTL data, however, have been generated by assessing recognition of exogenous peptides. The present study compares HIV-1-specific CTL cross-clade epitope recognition of exogenously loaded peptides with suppression of HIV-1-infected cells. Despite apparently broad cross-clade reactivity of CTLs against the former, CTL suppression of HIV-1 strains with corresponding epitope sequences is significantly impaired. The functional avidity of CTLs for nonautologous clade epitope sequences is diminished, suggesting that CTLs can fail to recognize levels of infected endogenously derived cell-surface epitopes despite recognizing supraphysiologic exogenously added epitopes. These data strongly support clade-specific antiviral activity of CTLs and call into question the validity of standard methods for assessing cross-clade CTL activity or CTL antiviral activity in general.
Comment in
-
Measuring HIV-1-specific T cell immunity: how valid are current assays?J Infect Dis. 2008 Feb 1;197(3):337-9. doi: 10.1086/525288. J Infect Dis. 2008. PMID: 18184092 No abstract available.
Similar articles
-
Cross-clade-specific cytotoxic T lymphocytes in HIV-1-infected children.Virology. 1998 Oct 25;250(2):316-24. doi: 10.1006/viro.1998.9373. Virology. 1998. PMID: 9792842
-
Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda.J Infect Dis. 2000 Nov;182(5):1350-6. doi: 10.1086/315868. Epub 2000 Oct 9. J Infect Dis. 2000. PMID: 11023458 Clinical Trial.
-
Impact of intrinsic cooperative thermodynamics of peptide-MHC complexes on antiviral activity of HIV-specific CTL.J Immunol. 2009 May 1;182(9):5528-36. doi: 10.4049/jimmunol.0803471. J Immunol. 2009. PMID: 19380801
-
The HIV hide and seek game: an immunogenomic analysis of the HIV epitope repertoire.AIDS. 2009 Jul 17;23(11):1311-8. doi: 10.1097/QAD.0b013e32832c492a. AIDS. 2009. PMID: 19550286 Review.
-
Will we be able to 'spot' an effective HIV-1 vaccine?Trends Immunol. 2003 Feb;24(2):67-72. doi: 10.1016/s1471-4906(02)00034-0. Trends Immunol. 2003. PMID: 12547502 Review.
Cited by
-
T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge.J Virol. 2010 May;84(9):4352-65. doi: 10.1128/JVI.02365-09. Epub 2010 Feb 17. J Virol. 2010. PMID: 20164222 Free PMC article.
-
T cells target APOBEC3 proteins in human immunodeficiency virus type 1-infected humans and simian immunodeficiency virus-infected Indian rhesus macaques.J Virol. 2013 Jun;87(11):6073-80. doi: 10.1128/JVI.00579-12. Epub 2013 Mar 27. J Virol. 2013. PMID: 23536679 Free PMC article.
-
Minor viral and host genetic polymorphisms can dramatically impact the biologic outcome of an epitope-specific CD8 T-cell response.Blood. 2009 Aug 20;114(8):1553-62. doi: 10.1182/blood-2009-02-206193. Epub 2009 Jun 19. Blood. 2009. PMID: 19542300 Free PMC article.
-
Challenges in the design of a T cell vaccine in the context of HIV-1 diversity.Viruses. 2014 Oct 23;6(10):3968-90. doi: 10.3390/v6103968. Viruses. 2014. PMID: 25341662 Free PMC article. Review.
-
Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes.J Virol. 2009 Apr;83(7):3138-49. doi: 10.1128/JVI.02073-08. Epub 2009 Jan 21. J Virol. 2009. PMID: 19158248 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous